Inici ❯ Projectes d'investigació ❯ IMMUTOL (Advanced antigen-specific dendritic cell-based therapy to re-establish tolerance in immunemediated diseases)

IMMUTOL (Advanced antigen-specific dendritic cell-based therapy to re-establish tolerance in immunemediated diseases)

Investigador principal

Dr. Jordi Martorell López

Grup d'investigació

GEVAB – Grup d’Enginyeria Vascular i Biomedicina Aplicada

Font de finançament:

Unió Europea

Període:

01/05/2023 a 30/04/2027

Tipologia del projecte:

Projecte consorci europeu

Estat del projecte:

ACTIU

Entitat finançadora:

Comisión Europea (CE)

Financiació:

273,779 €

IMMUTOL is the Accelerated development and validation of an advanced therapeutic drug (ATMP) based on modified VitD3

The aim of IMMUTOL isthe fast-track development and validation of an advanced therapeutic medicinal product (ATMP) based on VitD3-modified tolerogenic DC for immunotherapy approaches.

Through a multidisciplinary approach, IMMUTOL will leverage the power of tolerogenic VitD3DC-based immunotherapy to develop a more potent and durable treatment for MS and, in turn other autoimmune inflammatory diseases with an unmet medical need. In parallel, it will bring information about tolerance mechanisms and patient-specific requirements for manufacturing effective tolDC products.
https://immutol-horizon.eu

Grups d'investigació

GEVAB – Grup d’Enginyeria Vascular i Biomedicina Aplicada

El grup GEVAB desenvolupa la seva activitat en dues grans àrees: el desenvolupament de biomaterials per a tractar patologies vasculars i l'estudi d'altres necessitats clíniques, integrant coneixements de medicina, biologia, química, física, matemàtiques i computació.